# Extracellular Vesicles in Ophthalmology: From Natural Nanocarriers to Engineered Therapeutics

## TL;DR

Extracellular vesicles are being developed as safe and effective carriers for eye disease treatments, with potential for personalized medicine.

## Contribution

The paper highlights recent advances in engineering extracellular vesicles for ocular therapies and outlines challenges for clinical translation.

## Key findings

- EVs can promote ocular surface repair and retinal neuroprotection with low immunogenicity.
- Induced pluripotent stem cell-derived EVs improve batch uniformity and enable personalized therapy.
- Standardization and clinical trials are needed to advance EV-based therapeutics for eye diseases.

## Abstract

Extracellular vesicles (EVs) are increasingly recognized as programmable bioactive carriers in non-viral gene delivery and adaptable bioengineering platforms. Beyond their roles as natural nanocarriers in intercellular communication, EVs can promote ocular surface repair and retinal neuroprotection with potential for low immunogenicity and high biocompatibility. Bioengineering now enables cargo encapsulation, surface targeting, and integration of EVs with biomaterial platforms to enhance tissue penetration, retention, and precision delivery. The emergence of induced pluripotent stem cell-derived EVs (iMSC-EVs) offers improved batch uniformity and potential for personalized therapy. However, progress hinges on resolving knowledge gaps in ocular EV biology, standardizing isolation and storage, scaling reproducible manufacturing, and executing focused clinical trials. We synthesize the current developments and outline how EVs are moving from biological mediators to engineered therapeutics to accelerate the translation of EV diagnostics and therapeutics for eye diseases.